Biological Products and Pharmacovigilance: Why Product Characteristics Matter

Purpose and Scope

The pharmacovigilance of a biological medicinal product begins with an understanding of what the product is biologically. A biological medicine is not defined only by its active-substance name or therapeutic indication. Its relevant characteristics may depend on molecular structure, biological activity, source material, expression system, manufacturing process, purification, formulation, storage and administration. These characteristics determine not only how the product produces its intended effect, but also which safety questions can arise and how post-authorisation evidence should be interpreted.

This relationship between product characteristics and safety surveillance is particularly important because biological medicines comprise several scientifically distinct groups. A plasma-derived immunoglobulin, a recombinant coagulation factor, a monoclonal antibody, a vaccine and a gene therapy are all biological medicinal products, but they do not share the same sources of uncertainty or the same mechanisms of potential harm. The general pharmacovigilance system remains applicable across them, while the scientific interpretation of safety evidence must be adapted to the product.

The purpose of this article is to explain that connection. It examines the product characteristics that most directly influence pharmacovigilance, beginning with molecular and biological properties and progressing through manufacturing, immunogenicity, product identity, traceability, exposure and lifecycle change. It then translates these characteristics into practical consequences for case processing, signal management, risk management, aggregate evaluation and inspection readiness.

The article does not attempt to reproduce the detailed pharmacovigilance framework covered elsewhere in QPPV.com. Instead, it provides the scientific bridge between the biological-product taxonomy established in the preceding articles and the type-level articles that follow. The central principle is that biological-product pharmacovigilance depends on preserving enough product and exposure information to determine what was administered and to interpret the resulting safety evidence at the appropriate level.

From Biological Characteristics to Safety Surveillance

The connection between product characteristics and pharmacovigilance can be understood as a chain. The biological nature of a product determines particular molecular and functional characteristics. Those characteristics are influenced by how the product is produced and controlled. The resulting product is administered to a defined population under particular clinical conditions. Safety events then arise from a combination of product-related, patient-related, disease-related and treatment-related factors. Pharmacovigilance must collect and evaluate evidence across that chain rather than considering the adverse event in isolation.

A simplified model is:

biological source and structure → manufacturing and product characteristics → exposure → biological response → clinical event → safety evidence → pharmacovigilance assessment

The arrows do not imply that every event can be traced mechanistically through every step. Many adverse events have multifactorial causes, and an observed association does not establish causality. The model instead identifies the information needed to assess whether a plausible relationship exists and whether the concern is specific to an individual product, a group of related products, a manufacturing state or a broader therapeutic mechanism.

This is why product knowledge matters during routine case assessment as well as during formal signal evaluation. If the product cannot be identified correctly, the evidence may be assigned to the wrong product. If exposure cannot be established, the event may be difficult to interpret in relation to treatment. If the relevant biological mechanism is misunderstood, a potential signal may be overlooked or an unrelated event may be incorrectly attributed to the product.

The objective is therefore not to make every pharmacovigilance professional a specialist in every biological technology. It is to ensure that the pharmacovigilance system has access to the product information and scientific expertise necessary to interpret safety evidence appropriately.

Molecular Structure and Biological Activity

The first product characteristic relevant to pharmacovigilance is the biological substance itself. Structure determines many aspects of biological activity, including target binding, receptor interaction, enzymatic activity, antigenicity, distribution and elimination. For complex biological substances, structural attributes can include higher-order conformation, glycosylation, aggregation, charge variants and other molecular characteristics that may influence activity or immunogenicity.

The relevance of these attributes differs between product types. A therapeutic enzyme may depend on catalytic activity and substrate recognition. A monoclonal antibody may depend on antigen binding and, depending on its design and mechanism, Fc-mediated functions. A coagulation factor may depend on precise functional activity within a complex physiological pathway. A vaccine depends on the properties of its antigenic components and the immune response they generate. A cell therapy introduces a different set of characteristics because the administered product consists of living cells whose behaviour may change after administration.

The pharmacovigilance implication is that the same adverse-event term can have different scientific meanings across biological modalities. An injection-site reaction, for example, may be a local administration effect, an immune-mediated reaction or part of a broader hypersensitivity response. Similarly, reduced clinical response may represent disease progression, inadequate exposure, neutralising antibodies, an issue with administration, or another cause. Product-specific scientific context is therefore required before the event can be interpreted.

This also explains why evidence from related products should be used carefully. Biological medicines may share a mechanism or therapeutic target, but similarity at one level does not establish identical safety behaviour at another. EMA's immunogenicity guidance specifically emphasises that therapeutic proteins should be considered as individual products and that experience from related proteins is supportive rather than automatically determinative. [1]

Product Characteristics Beyond the Active Substance Name

An active-substance name provides an essential identifier, but it does not contain all the information needed for biological-product pharmacovigilance. Product characteristics can include formulation, strength, route of administration, presentation, manufacturing site, production process, relevant quality attributes and, where appropriate, batch information.

The importance of these distinctions becomes apparent when related products coexist. A reference biological product and a biosimilar may contain highly similar active substances, yet they remain distinct medicinal products with their own product identities and manufacturing processes. Similarly, two products directed at the same biological target may have different structures, formulations, pharmacokinetics or immunogenicity profiles.

The correct pharmacovigilance level therefore depends on the question being asked. A therapeutic class may be appropriate when considering biological plausibility. A product family may be appropriate when comparing mechanisms or identifying a potential class-related concern. Product-level identification is required when assessing whether a reported event is associated with a particular medicinal product. Batch-level information may become important when investigating a potential quality or manufacturing-related concern.

These levels should complement rather than replace one another. The pharmacovigilance system should be capable of moving from the individual case to the product and, where justified by the evidence, from the product to the relevant class or mechanism.

Manufacturing as a Product Characteristic

For many biological medicines, the manufacturing process is closely connected to the characteristics of the final product. Biological substances may be produced using living organisms, cell cultures or other biological systems, and the resulting material may require multiple purification and formulation steps. The process can influence attributes that are relevant to quality, biological activity and immunogenicity.

This does not mean that the manufacturing process should be treated as an independent source of adverse reactions in every case. Rather, manufacturing is part of the scientific context in which product quality and consistency are established. When a process changes, the regulatory assessment asks whether the product before and after the change remains comparable with respect to relevant quality attributes and, ultimately, safety and efficacy.

ICH Q5E provides principles for assessing comparability of biotechnology-derived and biological products following manufacturing-process changes. Its purpose is to establish evidence that a change has not adversely affected quality, safety or efficacy; it does not prescribe a single analytical, non-clinical or clinical strategy. [2]

For pharmacovigilance, the consequence is that information about significant manufacturing changes can become relevant when interpreting post-authorisation safety data. A temporal association between a manufacturing change and a cluster of reports may justify investigation, but the temporal association alone does not establish that the change caused the events. The appropriate assessment requires integration of product-quality information, batch data, clinical reports, exposure information and other evidence.

Product Quality and the Safety Profile

The quality characteristics of a biological medicinal product provide the foundation for its intended biological performance. Relevant attributes vary by modality but can include identity, purity, potency, structural characteristics, impurities and stability. Some characteristics may have a direct relationship with pharmacological activity, while others may affect the potential for unwanted immune responses or other safety concerns.

Pharmacovigilance does not duplicate the quality-control system. Quality control and quality assurance establish whether the product meets applicable specifications and manufacturing requirements. Pharmacovigilance evaluates safety information arising from clinical use and integrates that information with other evidence. The two systems nevertheless need effective interfaces because a clinical safety observation may raise a quality question, and a quality event may create a safety-relevant hypothesis requiring clinical surveillance.

This distinction is especially important when a potential quality defect is suspected. The pharmacovigilance function should not independently conclude that a product-quality problem exists merely because several cases share a product or batch. Conversely, the existence of a quality investigation does not by itself establish a clinical safety signal. The two assessments should remain scientifically and procedurally distinct while sharing relevant information through defined governance pathways.

Immunogenicity as a Product-Specific Safety Dimension

Immunogenicity is one of the clearest examples of why biological-product characteristics matter to pharmacovigilance. An administered biological substance can induce an immune response against the product or, in some circumstances, against a related endogenous target. The clinical significance of that response varies widely. Some immune responses may have no observable clinical consequence, whereas others can alter pharmacokinetics, reduce therapeutic activity or contribute to clinically important adverse reactions.

The occurrence and significance of immunogenicity depend on both product-related and patient-related factors. Product-related factors can include molecular structure, aggregation, impurities, formulation and manufacturing characteristics. Patient- and disease-related factors can include genetics, underlying disease, immune status, concomitant treatment and previous exposure to related proteins. Route and duration of administration can also influence the observed immune response. EMA's current immunogenicity guideline therefore treats immunogenicity as a product- and population-specific scientific assessment rather than a fixed property that can be inferred from product class alone. [1]

For pharmacovigilance, the important distinction is between the detection of an immune response and the demonstration of a clinically meaningful consequence. Anti-drug antibodies, for example, may be detected without a corresponding adverse reaction or loss of efficacy. Conversely, an immune response may become clinically important through effects on exposure, pharmacological activity or hypersensitivity. Interpretation therefore requires integration of immunogenicity data with clinical events, treatment response, pharmacokinetics and other relevant evidence.

This distinction also affects signal detection. A report describing loss of efficacy after prolonged treatment may be relevant to an immunogenicity hypothesis, but it does not establish that anti-drug antibodies caused the loss of response. The assessment may require information about antibody testing, timing, drug concentrations, disease activity, adherence, concomitant treatment and alternative explanations. The pharmacovigilance question is consequently broader than whether an antibody was detected.

Product Identity and Traceability

The ability to identify the biological product accurately is a practical prerequisite for meaningful surveillance. EMA's product-specific GVP guidance emphasises continuous product and batch traceability because biological medicines can undergo manufacturing changes over their lifecycle and because different products with related active substances need to remain distinguishable. [3]

Product identification has several dimensions. At minimum, the pharmacovigilance system should be capable of distinguishing the medicinal product from other products that may share an active substance name or therapeutic indication. Where relevant, it should also preserve information about formulation, strength, presentation and batch. The appropriate level of detail depends on the product and the safety question, but loss of identity at an early stage can make later investigation impossible.

Traceability is particularly important when the same active substance or a related biological substance is represented by multiple medicinal products. If reports are pooled without preserving the actual product identity, a product-specific signal may be diluted across unrelated products or a class-level interpretation may be incorrectly attributed to an individual product. Conversely, separating evidence that should legitimately be considered together can reduce the ability to recognise a broader biological or mechanism-related concern.

EMA's guidance also links traceability to the ability to locate affected products and, where necessary, patients when a safety or quality concern emerges. The operational implementation may vary between healthcare settings and countries. Electronic record linkage, dispensing records, administration records and barcode systems can all contribute to maintaining the required information. [3]

Traceability is therefore not merely an administrative data field. It is an evidentiary control that determines whether later pharmacovigilance analysis can reconstruct the relationship between product, exposure and event.

Exposure Context and Clinical Interpretation

The meaning of a safety event depends partly on the circumstances in which the biological product was administered. Relevant exposure information can include indication, dose, schedule, route, duration of treatment, previous exposure, concomitant medicines and the patient's underlying disease. For some biological products, treatment may be intermittent or lifelong; for others, administration may occur as a single treatment with effects that persist for an extended period.

These differences influence both the kinds of events that may be observed and the time during which they can plausibly emerge. A short-lived infusion reaction requires a different temporal assessment from a delayed immune-mediated event. A product whose biological activity persists after administration may require surveillance for effects that cannot be understood from the administration date alone. For vaccines, interpretation may additionally depend on age, dose number, vaccination schedule, coadministration and the background incidence of events in the vaccinated population.

Exposure information also matters when estimating the frequency of events. A case count without a suitable denominator does not establish incidence or comparative risk. The appropriate exposure measure depends on the product and the question being addressed. Patient numbers, doses administered, treatment cycles, treatment duration or person-time may each be relevant in different settings. The biological characteristics of the product therefore influence not only case interpretation but also the design and interpretation of post-authorisation safety studies and aggregate analyses.

Manufacturing Changes and Comparability

Biological medicines may undergo manufacturing changes for reasons such as process improvement, scale-up, facility changes, formulation development or other lifecycle requirements. Because manufacturing can influence product characteristics, changes are evaluated through a comparability framework rather than assumed to be clinically irrelevant.

ICH Q5E establishes principles for comparing biological products before and after manufacturing changes. The assessment focuses on relevant quality attributes and considers whether observed differences could affect safety or efficacy. The guideline recognises that the appropriate evidence depends on the nature and extent of the change. [2]

Pharmacovigilance becomes relevant because post-authorisation clinical use provides an additional source of evidence about the product after a change. If a potential safety concern appears to increase after a manufacturing transition, the assessment should consider whether the observation is real, whether the timing is compatible with the change, whether exposure is correctly classified, whether the affected batches can be identified and whether quality or analytical evidence provides biological plausibility.

The relationship should remain bidirectional. Pharmacovigilance observations may contribute to the assessment of a manufacturing-related concern, while information from quality and regulatory functions may alter the context in which safety reports are evaluated. Neither function should replace the scientific role of the other.

Biosimilars and Related Biological Products

Biosimilars provide a particularly important example of product-level interpretation. A biosimilar is developed through a regulatory comparability framework intended to demonstrate high similarity to a reference biological medicinal product, while recognising that biological products cannot generally be characterised as identical in the same way as simple chemically synthesised substances.

For pharmacovigilance, the existence of a reference product does not remove the need for product-specific identification. A safety report should identify the actual medicinal product involved wherever possible. This permits product-specific safety concerns to be detected and evaluated while allowing evidence to be considered in the context of the reference product and related biological products.

The same principle applies when considering switching or substitution. These practices raise questions about product exposure history and attribution, but the regulatory position concerning interchangeability and substitution is not determined solely by pharmacovigilance guidance. In the EU, prescribing and substitution practices fall within the responsibilities of Member States. [3]

Pharmacovigilance therefore needs to preserve the sequence of products received by a patient when that information is relevant. A patient may have been exposed to a reference product, one or more biosimilars, or other related biological products over time. Without an accurate treatment history, a subsequent event may be difficult to attribute and longitudinal safety assessment may lose important context.

From Product Characteristics to Signal Detection

Signal detection for biological medicines uses the same general pharmacovigilance concepts that apply to other medicinal products, but the interpretation of a potential signal may require more detailed product knowledge. The first task remains to determine whether the observed information represents a new or changing evidence pattern that warrants further evaluation. Product characteristics then help determine which hypotheses are scientifically plausible and what additional evidence should be sought.

For example, a cluster of reports may raise different questions depending on whether the product is a vaccine, a monoclonal antibody, a plasma-derived product or a gene therapy. Relevant hypotheses may involve pharmacological action, immune response, administration, manufacturing, product quality, patient selection or an interaction between these factors. The product category narrows the scientific possibilities, but it does not by itself determine the conclusion.

A useful assessment sequence is:

The table is a framework for inquiry, not a mandatory sequence for every signal. Different safety questions require different evidence. The essential principle is that product characteristics should inform the hypotheses being tested without becoming a substitute for evidence.

Integrating Product Characteristics Into the Pharmacovigilance System

Product-specific scientific knowledge becomes operationally useful only when it is connected to the pharmacovigilance system. The system must capture the information needed to identify the product, preserve relevant exposure history, recognise medically important patterns and escalate questions to the functions that hold complementary evidence.

For case processing, this means that product identification should be treated as a substantive part of case quality rather than a clerical detail. When the product is uncertain, the uncertainty should be preserved and resolved where possible rather than silently converted into an assumption. Relevant batch information should likewise be retained when available, particularly where the product or safety concern makes batch-level investigation meaningful.

For signal management, the product characteristics provide scientific context for hypothesis generation and evidence integration. They can help identify plausible mechanisms, relevant subgroups, expected time courses and useful data sources. They do not replace the formal signal-management process or establish causality by themselves.

For risk management and aggregate reporting, product characteristics help determine which risks need to be characterised and how new evidence should be interpreted against the existing safety specification. A change in observed risk may result from increased reporting, changes in exposure, a change in the treated population, improved diagnostic recognition, a manufacturing transition or a genuine change in the underlying safety profile. Product knowledge helps distinguish these possibilities, but the conclusion must remain evidence-based.

Roles and Interfaces

Biological-product pharmacovigilance requires effective interfaces because no single function normally holds all the information needed to interpret a complex safety observation. Pharmacovigilance may hold the case and signal data, while clinical or medical functions provide disease and treatment context, quality functions hold manufacturing and product-quality information, regulatory functions hold the authorised product and regulatory history, and epidemiology or pharmacoepidemiology functions may provide population-level evidence.

The purpose of these interfaces is not to merge different regulatory responsibilities. Each function retains its defined role. The purpose is to ensure that a safety assessment is based on the complete evidence relevant to the question being asked.

A useful governance model is:

The exact organisational structure varies between companies, but the evidence interfaces should be defined clearly enough that a safety concern involving a biological product can be investigated without uncertainty about who owns the relevant information.

Evidence and Records

The evidence required for effective biological-product pharmacovigilance extends beyond the individual safety report. Depending on the product and safety question, relevant records can include product identifiers, batch information, treatment dates, dose and route, manufacturing-change information, quality investigations, immunogenicity data, clinical evidence, epidemiological studies, signal assessments and regulatory decisions.

The objective is not to collect every possible data element in every case. Excessive data collection can create operational burden without improving interpretation. Instead, the system should retain information that is proportionate to the product's characteristics and the safety question under investigation.

Traceability is particularly valuable because it preserves the ability to connect evidence retrospectively. A report that initially appears unrelated to manufacturing may become relevant if a cluster is later identified in one production period. Conversely, a suspected batch pattern may disappear when product identity and exposure dates are verified. The evidentiary value of the original records therefore depends on their accuracy and retrievability.

This principle also applies to changes in product identity or presentation over time. Historical records should remain interpretable after variations, manufacturing changes, acquisitions, transfers or other lifecycle events. A pharmacovigilance system that cannot reconstruct which product was supplied and administered during a historical period may be unable to answer an important safety question years later.

Common Failure Modes

Several failure modes can arise when biological-product characteristics are not adequately incorporated into pharmacovigilance. These are potential scenarios for process evaluation, not claims about specific inspection findings.

Loss of product specificity. Reports involving related biological products are pooled under a broad active-substance or therapeutic-class label, preventing reliable product-level signal assessment.

Incomplete batch information. Batch data are available at the point of administration but are not transferred into the pharmacovigilance record, limiting later investigation of a potential quality or manufacturing pattern.

Overinterpretation of class effects. A safety observation associated with one product is assumed to apply to every product in the same class without sufficient evidence of a common mechanism or risk.

Underrecognition of shared mechanisms. Product-specific surveillance is conducted so narrowly that evidence from related products, the biological mechanism or the broader literature is not considered when a shared risk is scientifically plausible.

Confusion between manufacturing change and safety signal. A temporal association between a process change and subsequent reports is treated as evidence of causation without integrating quality, clinical, epidemiological and exposure evidence.

Immunogenicity treated as a binary finding. Detection of anti-drug antibodies is interpreted as proof of clinical harm, or absence of detected antibodies is interpreted as proof that an immune mechanism is impossible, without considering assay characteristics, timing, clinical consequences and other evidence.

Incomplete exposure history. Previous biological products, switching, treatment interruptions or relevant concomitant exposures are not reconstructed when they are needed to interpret the event.

These failure modes have a common underlying problem: the pharmacovigilance system loses the connection between the product, the exposure and the clinical evidence.

Inspection Perspective

An inspection of biological-product pharmacovigilance could examine whether the organisation has translated known product characteristics into effective operational controls. The relevant question is not whether personnel can recite the biological properties of a product, but whether those properties are reflected in the evidence and governance needed to operate the safety system.

Illustrative inspection questions include:

• Can the organisation reliably identify the biological product involved in an individual safety report?
• Can batch information be retrieved when it is relevant to the product or safety concern?
• Is there a defined process for obtaining relevant manufacturing and quality information when a safety assessment raises a potential product-quality question?
• Can treatment history be reconstructed when patients have received related biological products?
• Are immunogenicity findings interpreted in their clinical and product-specific context?
• Are product characteristics considered when developing and evaluating safety hypotheses?
• Are interfaces between pharmacovigilance, quality, medical, regulatory and epidemiological functions defined and evidenced?
• Can historical product and exposure information be retrieved sufficiently to support retrospective signal evaluation?

These questions are illustrative rather than descriptions of actual regulatory findings. An effective inspection response would be supported by documented processes, records, decision-making evidence and examples demonstrating that the controls work in practice.

Practical Implementation

A proportionate implementation can be built around five linked controls: product knowledge, identification, exposure reconstruction, scientific interfaces and evidence retention.

These controls should be proportionate to the product and its risk profile. A highly complex cell or gene therapy may require more specialised information and longer-term evidence retention than a conventional biological product, while a hospital-administered biological may require different traceability arrangements from a product supplied through community pharmacy.

Relationship With the Wider Pharmacovigilance Framework

Product characteristics do not constitute a separate pharmacovigilance system. They provide the scientific context in which the general system operates. Case management, signal management, risk management, aggregate reporting, safety communication, quality management and regulatory interaction retain their established roles, while biological-product knowledge determines how evidence within those processes should be interpreted.

This distinction prevents two opposite errors. The first is to treat biological products as though they require no adaptation of the general pharmacovigilance approach. The second is to create a completely separate biological-product system that duplicates general GVP processes without adding scientific value. The appropriate approach is to preserve the common pharmacovigilance architecture while introducing product-specific controls where biological characteristics create additional uncertainty or traceability requirements.

The relationship can therefore be expressed as:

general pharmacovigilance framework + product-specific scientific knowledge + appropriate evidence controls = effective biological-product surveillance

The same principle will apply throughout the QPPV.com biological-product series. Type-level articles will explain the characteristics of major biological families; subsequent subtype articles will identify characteristics that materially alter safety interpretation; and individual-product articles will examine the evidence specific to the authorised product. This layered structure allows the reader to move from general biological principles to product-specific safety evidence without treating every biological medicine as though it had the same risk profile.

Key Takeaways

Biological-product pharmacovigilance depends on understanding the product as more than an active-substance name. Molecular structure, biological activity, manufacturing, product quality, immunogenicity, formulation, exposure history and traceability can all influence how safety evidence should be collected and interpreted.

Manufacturing is particularly important because biological-product characteristics may depend on the production process. Manufacturing changes are evaluated through comparability principles, and pharmacovigilance provides post-authorisation clinical evidence that can contribute to the assessment of whether the safety profile remains consistent. A manufacturing change is not, by itself, a safety signal, and a safety signal is not, by itself, proof of a manufacturing defect.

Immunogenicity illustrates the need for product-specific interpretation. An immune response may have no clinical consequence or may affect safety, efficacy or exposure. Its significance therefore depends on the product, patient, disease, timing and clinical evidence rather than on the detection of antibodies alone.

Traceability provides the evidentiary link between product and event. Preserving product and batch identity, treatment history and relevant exposure information allows the pharmacovigilance system to distinguish product-specific concerns from broader class effects and to investigate potential manufacturing or quality patterns when justified.

The practical objective is a pharmacovigilance system that can connect what the product is, what was administered, to whom, when, what happened, what other explanations exist, and what the total evidence shows. That connection is the foundation for scientifically credible biological-product safety surveillance.

References

1. European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins — Revision 1. EMA/CHMP/BMWP/14327/2006 Rev. 1. Current effective version, legal effective date 1 December 2017.
2. International Council for Harmonisation. ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. CPMP/ICH/5721/03. European Medicines Agency, Step 5.
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Product- or Population-Specific Considerations II: Biological medicinal products. EMA/CHMP/PhVWP/463142/2012 Rev. 1.
4. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. In particular Annex I and the provisions concerning biological medicinal products and pharmacovigilance.
5. European Parliament and Council. Regulation (EC) No 726/2004, as amended, laying down Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products and establishing the European Medicines Agency.
6. European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in-vivo clinical use. EMA/CHMP/BMWP/86289/2010.
7. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), including the general modules relevant to pharmacovigilance systems, signal management, risk management, post-authorisation safety studies and quality systems.

Regulatory Note

This article distinguishes scientific interpretation from legal and regulatory requirements. The EU pharmacovigilance framework and applicable legislation establish mandatory requirements; EMA GVP guidance and scientific guidelines provide regulatory guidance and recommendations within that framework; operational controls described in this article are practical approaches and should not be interpreted as additional legal requirements unless the applicable legislation or guidance expressly requires them. The discussion of manufacturing changes, immunogenicity, traceability and related biological-product characteristics is intended to support pharmacovigilance interpretation and does not replace product-specific quality, clinical, regulatory or scientific assessments. Current legislation, EMA guidance, product information and relevant regulatory decisions should be checked before applying any requirement operationally.